Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093791 | 1.00 | ALOX5 (0.40) | ALOX5SMN1; SMN2ALDH1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL4104168 | 0.90 | ALOX5 (0.41) | ALOX5SMN1; SMN2ALDH1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL4097059 | 0.90 | ALOX5 (0.41) | ALOX5SMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL14810598 | 0.83 | ALOX5 (0.43) | ALOX5SMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL14810601 | 0.83 | ALOX5 (0.43) | ALOX5SMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL14810615 | 0.82 | ALOX5 (0.40) | ALOX5SMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL14810617 | 0.82 | ALOX5 (0.40) | ALOX5SMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL14810229 | 0.82 | ALOX5 (0.39) | ALOX5SMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL14810226 | 0.82 | ALOX5 (0.39) | ALOX5SMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL1254008 | 0.81 | ALOX5 (0.41) | ALOX5SMN1; SMN2ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | claimed |
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-1973902-A2 | 3-HETEROCYCLYLACRYLAMIDE COMPOUNDS AS FABI INHIBITORS AND ANTIBACTERIAL AGENTS | Affinium Pharmaceuticals, Inc. (CA) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007067416-A2 | HETEROCYCLYLACRYLAMIDE COMPOUNDS AS FABI INHIBITORS AND ANTIBACTERIAL AGENTS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | GAA, TFPI, DBI | ALOX5 2681/4885SMN1; SMN2 4069/4885ALDH1A1 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.